Trial Profile
Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs Adefovir (Primary) ; Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms ALTER
- Sponsors GSK
- 14 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
- 13 Mar 2012 New trial record